StateHouse Holdings Past Earnings Performance
Past criteria checks 0/6
StateHouse Holdings's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 0.1% annually. Revenues have been growing at an average rate of 21.2% per year.
Key information
-38.1%
Earnings growth rate
8.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 21.2% |
| Return on equity | n/a |
| Net Margin | -52.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How StateHouse Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 104 | -55 | 49 | 0 |
| 31 Mar 24 | 101 | -57 | 51 | 0 |
| 31 Dec 23 | 101 | -50 | 53 | 0 |
| 30 Sep 23 | 101 | -228 | 57 | 0 |
| 30 Jun 23 | 106 | -232 | 62 | 0 |
| 31 Mar 23 | 116 | -243 | 70 | 0 |
| 31 Dec 22 | 108 | -243 | 65 | 0 |
| 30 Sep 22 | 98 | -72 | 56 | 0 |
| 30 Jun 22 | 84 | -49 | 45 | 0 |
| 31 Mar 22 | 65 | -34 | 33 | 0 |
| 31 Dec 21 | 60 | -26 | 31 | 0 |
| 30 Sep 21 | 58 | -4 | 32 | 0 |
| 30 Jun 21 | 59 | -9 | 32 | 0 |
| 31 Mar 21 | 59 | -12 | 30 | 0 |
| 31 Dec 20 | 60 | -12 | 28 | 0 |
| 30 Sep 20 | 59 | -52 | 28 | 0 |
| 30 Jun 20 | 53 | -51 | 27 | 0 |
| 31 Mar 20 | 50 | -55 | 31 | 0 |
| 31 Dec 19 | 47 | -49 | 32 | 0 |
| 30 Sep 19 | 36 | -5 | 27 | 0 |
| 30 Jun 19 | 34 | -8 | 27 | 0 |
| 31 Mar 19 | 27 | -8 | 21 | 0 |
| 31 Dec 18 | 21 | -18 | 19 | 0 |
| 30 Sep 18 | 25 | -18 | 20 | 0 |
| 31 Dec 17 | 15 | -6 | 11 | 0 |
| 31 Dec 16 | 6 | -3 | 7 | 0 |
Quality Earnings: STHZ.F is currently unprofitable.
Growing Profit Margin: STHZ.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STHZ.F is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare STHZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STHZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.7%).
Return on Equity
High ROE: STHZ.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.